| 吉西他滨治疗晚期非小细胞肺癌的现状 |
| |
| 引用本文： | 罗扬,张湘茹.吉西他滨治疗晚期非小细胞肺癌的现状[J].中国癌症杂志,2001,11(1):74-77,80. |
| |
| 作者姓名： | 罗扬 张湘茹 |
| |
| 作者单位： | 中国医学科学院肿瘤医院内科, |
| |
| 摘 要： | 吉西他滨是近年来治疗晚期非小细胞肺癌的有效新药。国外大量临床试验已经证实其单一用药有效率稳定在20%以上，中位生存34周，可明显改善肿瘤相关症状，毒性易耐受，本文综述吉西他滨治疗晚期非小细胞肺癌的临床结果。
|
| 关 键 词： | 晚期非小细胞肺癌 吉西他滨 药物治疗 |
| 文章编号： | 1007-3639(2001)01-0074-04 |
The activity of gemcitabine in advanced non-small-cell lung cancer |
| |
| LUO Yang,ZHANG Xiang ru.The activity of gemcitabine in advanced non-small-cell lung cancer[J].China Oncology,2001,11(1):74-77,80. |
| |
| Authors: | LUO Yang ZHANG Xiang ru |
| |
| Abstract: | Gemcitabine is a new active drug in the treatment of advanced non small cell lung cancer (NSCLC). It is validated that the response rate of the single agent gemcitabine was consistently above 20%, median survival was 34 weeks and it could improve the disease related symptoms with well toleranced toxicities by many clinical studies. This report reviews the clinical studies of gemcitabine in the patients with advanced NSCLC. |
| |
| Keywords: | lung tumor non small cell lung cancer gemcitabine |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
